Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia

I. Fuzaylova
C. Lam
O. Talreja
A. N. Makaryus, Zucker School of Medicine at Hofstra/Northwell
D. Ahern
M. Cassagnol

Abstract

© The Author(s) 2019. Sacubitril/valsartan (Entresto®) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved for use in heart failure patients with a reduced ejection fraction. It is a combination drug that contains sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Our report outlines a case of probable ARNI-induced hyponatremia occurring in an elderly woman with heart failure with a reduced ejection fraction. According to Naranjo Adverse Drug Reaction Assessment, score indicated a likely association between patient’s hyponatremia and her use of sacubitril/valsartan.